Jasper Therapeutics, Inc.
JSPR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001788028
No open-market purchases or sales by Jasper Therapeutics, Inc. insiders were filed in the last 90 days; 45 institutions reported holding it in 13F filings for Q2 2026, worth $5.05M in total; no superinvestor holds it.
Other share classesJSPRW
13F holders, Q4 2021
Institutional positions in Jasper Therapeutics, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- +16 vs. Q3 2021
- Shares held
- 20.9M
- +10.6M (+103.1%) vs. Q3 2021
- Total value
- $160.7M
- +$59.3M (+58.4%) vs. Q3 2021
- New holders
- 19
- 3 more added
- Sold out
- 3
- 2 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting JSPR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 45 | $5.05M |
| Q1 2026 | 58 | $13.9M |
| Q4 2025 | 55 | $35.2M |
| Q3 2025 | 60 | $47.8M |
| Q2 2025 | 65 | $69.5M |
| Q1 2025 | 69 | $56.1M |
| Q4 2024 | 88 | $334.5M |
| Q3 2024 | 81 | $274.8M |
| Q2 2024 | 69 | $329.8M |
| Q1 2024 | 61 | $380.2M |
| Q4 2023 | 42 | $61.2M |
| Q3 2023 | 41 | $63.7M |
| Q2 2023 | 46 | $120.0M |
| Q1 2023 | 45 | $168.8M |
| Q4 2022 | 23 | $9.57M |
| Q3 2022 | 23 | $15.7M |
| Q2 2022 | 23 | $37.5M |
| Q1 2022 | 24 | $69.6M |
| Q4 2021 | 25 | $160.7M |
| Q3 2021 | 9 | $101.4M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Jasper Therapeutics, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Qiming U.S. Ventures Management, LLC | 5,852,982 | $45.9M | 21.14% | +5,852,982 | New |
| Abingworth LLP | 5,628,558 | $44.1M | 10.69% | 00.0% | Unchanged |
| Velan Capital Investment Management LP | 3,219,036 | $22.9M | 19.17% | +3,219,036 | New |
| Citadel Advisors LLC | 3,046,156 | $22.8M | 0.02% | +41,121+1.4% | Added |
| Federated Hermes, Inc. | 1,206,577 | $9.47M | 0.02% | −293,423−19.6% | Reduced |
| Kingdon Capital Management, L.L.C. | 540,000 | $4.24M | 0.63% | +540,000 | New |
| Vanguard Group Inc | 483,503 | $3.79M | 0.00% | +483,503 | New |
| Morgan Stanley | 298,789 | $2.35M | 0.00% | +189,929+174.5% | Added |
| Grace Capital | 218,110 | $1.71M | 1.02% | +218,110 | New |
| BlackRock Inc. | 169,493 | $1.33M | 0.00% | +169,493 | New |
| Geode Capital Management, LLC | 117,050 | $918.0K | 0.00% | +117,050 | New |
| Vahanian & Associates Financial Planning Inc. | 25,000 | $196.0K | 0.16% | +25,000 | New |
| Virtu Financial LLC | 20,743 | $163.0K | 0.02% | +20,743 | New |
| Northern Trust Corp | 20,289 | $159.0K | 0.00% | +20,289 | New |
| Millennium Management LLC | 19,922 | $156.0K | 0.00% | +19,922 | New |
| Goldman Sachs Group Inc | 17,749 | $139.0K | 0.00% | +17,749 | New |
| Truist Financial Corp | 11,250 | $89.0K | 0.00% | +11,250 | New |
| Paloma Partners Management Co | 10,141 | $80.0K | 0.00% | +10,141 | New |
| Tower Research Capital LLC (TRC) | 2,914 | $23.0K | 0.00% | −6,039−67.5% | Reduced |
| Penserra Capital Management LLC | 2,727 | $21.0K | 0.00% | +2,727 | New |
| UBS Group AG | 2,552 | $20.0K | 0.00% | +2,013+373.5% | Added |
| Simplex Trading, LLC | 700 | $5.00K | 0.00% | +700 | New |
| Wells Fargo & Company | 251 | $2.00K | 0.00% | +251 | New |
| Ionic Capital Management LLC | 100 | $1.00K | 0.00% | +100 | New |
| SkyView Investment Advisors, LLC | 5 | $0 | 0.00% | +5 | New |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −26,030−100.0% | Sold out |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −201−100.0% | Sold out |